COLO B Coloplast A/S Class B

Coloplast strengthens ostomy care portfolio with three significant product launches

Coloplast strengthens ostomy care portfolio with three significant product launches

The company has received reimbursement approval in the UK for Heylo™, the world’s first digital leakage notification system, and expands its SenSura® Mio ostomy range with two new products.

  • As part of our 2025 strategy, Strive25, we set an ambition to significantly raise the standard of care for our users and bring new products to market at a higher pace. I am excited to see that our Innovation unit continues to deliver on this commitment, latest with these three new products in Ostomy Care, says Executive Vice President of Innovation, Nicolai Buhl.

Introducing Heylo

For many people living with a stoma, leakage is a significant physical and mental challenge in their daily life. Heylo is designed to detect potential leakages under the ostomy baseplate, and by notifying users at an early stage it enables them to take action and prevent the leakage from progressing. The product consists of a sensor layer that is attached to the baseplate, a transmitter that is attached to the sensor layer and connects to the user’s smartphone via Bluetooth®, and an app that notifies the user at the first sign of leakage and if it continues to spread.

  • Heylo is the world’s first digital leakage notification system and a big step forward in providing more personalised care for our users. I believe Heylo will help users feel more in control, bring peace of mind, reduce their fear of leakage, and ultimately improve quality of life, says Nicolai Buhl.

The first market to launch Heylo will be the UK, where national reimbursement has been granted as of 1 July 2024*.

Introducing SenSura® Mio in black and SenSura Mio Convex Soft with Flex coupling

Coloplast is also expanding its SenSura Mio range with two new products. The company is launching SenSura Mio in black, aiming to provide more product choice for people with a stoma.

  • We know that having more product choice matters to people adapting to life after stoma surgery and may even help people in accepting their condition. Black is neutral, discreet, and timeless – and our hope is that this new bag will empower users and give them confidence to live life on their terms, says Nicolai Buhl.

The first variants of the SenSura Mio in black will be introduced in key markets over the next six months, starting with Italy, France, Denmark, Norway, and the Netherlands in May 2024*.

Coloplast is also launching SenSura Mio Convex Soft with Flex coupling to reach more users that need convexity and 2-piece solutions. This product will be introduced in key markets over the next nine months, starting in Italy and France in May 2024*.

Contacts

Peter Mønster

Sr. Media Relations Manager



Aleksandra Dimovska

Sr. Director of Investor Relations



*Heylo, SenSura Mio in black, and SenSura Mio Convex Soft with Flex coupling are medical devices for which CE-mark has been affixed. Product availability is subject to the regulatory process of individual countries and is not guaranteed. These products are currently not available in the US.

Attachments



EN
07/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

 PRESS RELEASE

Coloplast A/S - Invitation to Coloplast's Meet the Management event on...

Coloplast A/S - Invitation to Coloplast's Meet the Management event on 6 June 2024 (gentle reminder) The event will take place on Thursday, 6 June 2024 at Coloplast’s HeadquartersHoltedam 3, 3050 Humlebaek, Denmarkfrom 11.30 - 18.00 CEST (Central European Summer Time) Coloplast invites institutional investors, equity analysts and media to attend our 2024 Meet the Management event.The event will be held in person at our headquarters in Humlebaek, Denmark, with the option to join us virtually for the plenary session.The purpose of the event is to provide participants with the opportuni...

 PRESS RELEASE

Coloplast udvider Luja™-portefølje med nyt kateter til kvinder

Coloplast udvider Luja™-portefølje med nyt kateter til kvinder Engangskateteret gør det muligt for kvinder at tømme blæren i et frit flow1, hvilket nedsætter risikoen for urinvejsinfektioner2. Luja-platformen er med sin Micro-hole Zone Technology en ny generation af intermitterende engangskatetre til mennesker med behov for hjælp til at tømme deres blære. Efter en vellykket lancering af Luja til mandlige kateterbrugere lancerer Coloplast nu Luja til kvinder. ”Vi har modtaget rigtig god feedback for Luja til mænd i vores produktevalueringer. Næsten alle sundhedsprofessionelle anbefaler kat...

 PRESS RELEASE

Coloplast expands its Luja™ portfolio with next generation catheter fo...

Coloplast expands its Luja™ portfolio with next generation catheter for women The female intermittent catheter enables complete bladder emptying in one free flow1, aiming to reduce the risk of urinary tract infections2. Following the successful launch of Luja with Micro-hole Zone Technology, a next generation intermittent catheter for men, Coloplast is now launching Luja for women. “So far, we have received great feedback on Luja for men in our product evaluations. Nearly all healthcare professionals would recommend the male catheter to their patients3, and sev...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen

Mixed emotions about Kerecis

Q2 EBIT was 3-4% below expectations. Kerecis goodwill writedown is a troublesome read. Too expensive, too-low EPS growth and too many questions: SELL.

Rune Majlund Dahl
  • Rune Majlund Dahl

Coloplast (Buy, TP: DKK1050.00) - Next up: ‘Meet the Management’

Q2 organic growth of 7.5% YOY was in line with our forecast and consensus, but the EBIT margin (b.s.i.) of 27.2% missed. Coloplast revised its 2023/24 reported revenue growth guidance to 10–11% (previously c11%) on FX, but kept its c8% organic growth and 27–28% EBIT margin (b.s.i.) guidance. At the upcoming ‘Meet the Management’ event, we expect an update on its clinical performance programme and a deep-dive into Kerecis. We reiterate our BUY and DKK1,050 target price.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch